Indigenisation of Biologics (InBx) - A National Biologics Catapult
In response to the growing need for indigenous biomanufacturing capabilities in India, the Indigenisation of Biologics (InBx) initiative was launched on 1st of August, 2024 under the aegis of C-CAMP, leveraging our expertise and infrastructure at the Bangalore Life Sciences Cluster (BLiSC). Building on the success of the Indigenisation of Diagnostics (InDx) program, InBx aims to accelerate the development and production of biotherapeutics, including enzymes, monoclonal antibodies, and recombinant proteins.
With the aim to establish India as a global leader in biomanufacturing, the goal of the InBx program, through a public-private partnership, is to bring together diverse stakeholders to establish India as a global hub for biologics. This initiative seeks to create a robust ecosystem for biomanufacturing, ensuring international quality standards and scaling capacities to meet global demand.
C-CAMP InBx has established a comprehensive framework, featuring Digital Platforms and Centres of Excellence (CoEs) to support its mission. The program is dedicated to handholding Indian MSMEs, startups, and researchers, providing end-to-end support from product development to market launch.
Why InBx?
- State-of-the-Art Infrastructure: Access advanced facilities for biomanufacturing.
- Expert Guidance: Benefit from the knowledge of experienced scientists and engineers.
- Collaborative Ecosystem: Engage with a network of industry leaders, academic institutions, and regulatory experts.
- Scalability and Quality: Achieve high-quality standards and scale-up production capacities.
Have a research challenge, a vision to indigenize, or a desire to scale-up? Get in touch with us! Let's partner to create an ecosystem for fully indigenized, high-quality biotherapeutics.
Join the cohort : Engage with us: inbx[at]ccamp.res.in
- Global Leadership: To establish a nationwide biologics platform positioning India as a global leader in biomanufacturing and therapeutic innovation.
- Advanced Biomanufacturing: To catalyze the innovation, development, and commercialization of high-quality, affordable biotherapeutics for India and the world, including cutting-edge therapies like cell and gene therapies.
- To empower and support the Indian biomanufacturing ecosystem in achieving self-sufficiency in producing biotherapeutics, enabling the country to not only meet domestic demands but also establish a significant presence in the global market.
- To ensure that Indian companies can develop world-class biomanufacturing processes and technologies, from upstream development to downstream processing and analytics, fostering a self-reliant and export-capable sector.
- Deep Expertise & Advanced Technology: Each CoE is led by accomplished senior researchers and industry experts, bringing together deep subject matter knowledge, academic excellence, and access to state-of-the-art technologies.
- Comprehensive End-to-End Services: Aligning with the broader mission of the National Biologics Catapult, the CoEs offer a full suite of services including quality assurance, process development, and technology scale-up for biotherapeutics such as recombinant proteins, monoclonal antibodies, and enzymes.
- Clinical and Process Validation: A network of Clinical Validation Centres is being established in partnership with premier medical centers and hospitals. These centers provide essential infrastructure and expertise for validating biotherapeutic products, ensuring they meet the highest clinical standards.
- Quality Enhancement: The CoEs play a critical role in enhancing the quality of indigenously manufactured biotherapeutics, including raw materials, reagents, and final products. They work to ensure these products meet global standards and regulatory requirements.
- Continuous Expansion: The network of CoEs and partners is continuously expanding to include new collaborations and capabilities, enhancing the scope and impact of the InBx initiative.
- Support for Commercialization: The CoEs provide invaluable support to startups, MSMEs, and established companies in the biomanufacturing sector, facilitating the commercialization of innovative biotherapeutics.